Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cinclus Pharma Holding ABFRA:J8P +9.75%2 EV-to-EBITDA is -0.96 as of Aug. 23, 2026. GuruFocus rates FRA:J8P with a GF Score™ of 2/100. The stock has 5 warning signs investors should review. Among 739 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 135317.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cinclus Pharma Holding AB's enterprise value is €25.37 Mil.
Cinclus Pharma Holding AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-26.51 Mil. Therefore, Cinclus Pharma Holding AB's EV-to-EBITDA for today is -0.96.
The historical rank and industry rank for Cinclus Pharma Holding AB's EV-to-EBITDA or its related term are showing as below:
FRA:J8P'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.96 Med: -1.43 Max: 0.37
Current: -0.97
During the past 5 years, the highest EV-to-EBITDA of Cinclus Pharma Holding AB was 0.37. The lowest was -8.96. And the median was -1.43.
FRA:J8P's EV-to-EBITDA is ranked worse than 100% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.21
vs FRA:J8P: -0.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cinclus Pharma Holding AB (FRA:J8P) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cinclus Pharma Holding AB's PE Ratio (TTM) for today is calculated as:
Cinclus Pharma Holding AB's share price for today is €1.126.
Cinclus Pharma Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's EV-to-EBITDA falls into.
Cinclus Pharma Holding AB's current Enterprise Value is €25.37 Mil.
Cinclus Pharma Holding AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cinclus Pharma Holding AB (FRA:J8P) has a EV-to-EBITDA of -0.96 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cinclus Pharma Holding AB. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 739 companies in the Drug Manufacturers industry.
Is Cinclus Pharma Holding AB's EV-to-EBITDA too high?
Cinclus Pharma Holding AB's current EV-to-EBITDA is -0.96. Based on the distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 739 companies for EV-to-EBITDA. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.21, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cinclus Pharma Holding AB. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current EV-to-EBITDA is -0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current EV-to-EBITDA of -0.96. The current EV-to-EBITDA is -0.96. Cinclus Pharma Holding AB's overall GF Score™ is 2/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current EV-to-EBITDA is -0.96 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
2GF Score
Get the complete analysis for FRA:J8P
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
